Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
Abstract
Recent studies have shown that drugs that are normally unable to cross the blood-brain barrier (BBB) following intravenous injection can be transported across this barrier by binding to poly(butyl cyanoacrylate) nanoparticles and coating with polysorbate 80. However, the mechanism of this transport so far was not known. In the present paper, the possible involvement of apolipoproteins in the transport of nanoparticle-bound drugs into the brain is investigated. Poly(butyl cyanoacrylate) nanoparticles loaded with the hexapeptide dalargin were coated with the apolipoproteins AII, B, CII, E, or J without or after precoating with polysorbate 80. In addition, loperamide-loaded nanoparticles were coated with apolipoprotein E alone or again after precoating with polysorbate 80. After intravenous injection to ICR mice the antinociceptive threshold was measured by the tail flick test. Furthermore, the antinociceptive threshold of polysorbate 80-coated dalargin-loaded nanoparticles was determined in ApoEtm1Unc and C57BL/6J mice. The results show that only dalargin or loperamide-loaded nanoparticles coated with polysorbate 80 and/or with apolipoprotein B or E were able to achieve an antinociceptive effect. This effect was significantly higher after polysorbate-precoating and apolipoprotein B or E-overcoating. With the apolipoprotein E-deficient ApoEtm1Unc mice the antinociceptive effect was considerably reduced in comparison to the C57BL/6J mice. These results suggest that apolipoproteins B and E are involved in the mediation of the transport of drugs bound to poly(butyl cyanoacrylate) nanoparticles across the BBB. Polysorbate 80-coated nanoparticles adsorb these apolipoproteins from the blood after injection and thus seem to mimic lipoprotein particles that could be taken up by the brain capillary endothelial cells via receptor-mediated endocytosis. Bound drugs then may be further transported into the brain by diffusion following release within the endothelial cells or, alternatively, by transcytosis.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Adsorption of a plasmatic protein such as apolipoprotein E onto the SLN surface could facilitate its uptake into the brain mediated by adherence to endothelial cells of the blood-brain barrier.
“Furthermore, the adsorption of a plasmatic protein such as the apolipoprotein E, onto SLNs surface could facilitate its uptake into brain mediated by adherence to the endothelial cells of the BBB”
From Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs (2020) · cites this paper as Kreuter et al., 2002
Cites
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703 · see citing works
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028 · see citing works
Three-Dimensional Structure of the LDL Receptor-Binding Domain of Human Apolipoprotein E
Wilson, C., Wardell, M. R., Weisgraber, K. H., Mahley, R. W., & Agard, D. A. (1991) · Science · doi:10.1126/science.2063194 · Cited by 678 · see citing works
Complete protein sequence and identification of structural domains of human apolipoprotein B
Knott, T. J., Pease, R. J., Powell, L. M., Wallis, S. C., Rall, S. C., Innerarity, T. L., Blackhart, B. D., Taylor, W. H., Marcel, Y. L., Milne, R. W., et al. (1986) · Nature · doi:10.1038/323734a0 · Cited by 619 · see citing works
A New Function for the LDL Receptor: Transcytosis of LDL across the Blood–Brain Barrier
Dehouck, B., Fénart, L., Dehouck, M., Pierce, A., Torpier, G., & Cecchelli, R. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.138.4.877 · Cited by 568 · see citing works
Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles)
Kreuter, J., Alyautdin, R. N., Kharkevich, D. A., & Aa, I. (1995) · Brain Research · doi:10.1016/0006-8993(95)00023-j · Cited by 538 · see citing works
Self-citationSignificant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles
Gulyaev, A. E., Gelperina, S. E., Skidan, I. N., Antropov, A. S., Kivman, G. Y., & Kreuter, J. (1999) · Pharmaceutical Research · doi:10.1023/a:1018983904537 · Cited by 521 · see citing works
Self-citationZlokovic, B. V., Martel, C. L., Matsubara, E., McComb, J. G., Zheng, G., McCluskey, R. T., Frangione, B., & Ghiso, J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4229 · Cited by 430 · see citing works
Human Apolipoprotein E Receptor 2
Kim, D.-H., Iijima, H., Goto, K., Sakai, J., Ishii, H., Kim, H.-J., Suzuki, H., Kondo, H., Saeki, S., & Yamamoto, T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.14.8373 · Cited by 384 · see citing works
Alyautdin, R. N., Petrov, V. E., Langer, K., Berthold, A., Kharkevich, D. A., & Kreuter, J. (1997) · Pharmaceutical Research · doi:10.1023/a:1012098005098 · Cited by 352 · see citing works
Self-citationIdentification of a major polypeptide of the nuclear pore complex.
Gerace, L., Ottaviano, Y. L., & Kondor-Koch, C. (1982) · The Journal of Cell Biology · doi:10.1083/jcb.95.3.826 · Cited by 323 · see citing works
Taub, M. L., Chuman, L. M., Saier, M. H., et al. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.7.3338 · Cited by 304 · see citing works
The Blood-brain Barrier: Principles for Targeting Peptides and Drugs to the Central Nervous System
Begley, D. J. (1996) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1996.tb07112.x · Cited by 291 · see citing works
Nerurkar, M. M., Burton, P. S., & Borchardt, R. T. (1996) · Pharmaceutical Research · doi:10.1023/a:1016033702220 · Cited by 287 · see citing works
Nanoparticle Technology for Delivery of Drugs Across the Blood–Brain Barrier
Schröeder, U., Sommerfeld, P., Ulrich, S., & Sabel, B. A. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js980084y · Cited by 275 · see citing works
Dehouck, B., Dehouck, M., Fruchart, J., & Cecchelli, R. (1994) · The Journal of Cell Biology · doi:10.1083/jcb.126.2.465 · Cited by 234 · see citing works
Reversal of multidrug resistance by surfactants
Woodcock, D., Linsenmeyer, M. E., Chojnowski, G. M., Kriegler, A., Nink, V., Webster, L., & Sawyer, W. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.217 · Cited by 233 · see citing works
Alyautdin, R. N., Tezikov, E. B., Ramge, P., Kharkevich, D. A., Begley, D. J., & Kreuter, J. (1998) · Journal of Microencapsulation · doi:10.3109/02652049809006836 · Cited by 229 · see citing works
Self-citationLipoprotein receptors: new roles for ancient proteins
Willnow, T. E., Nykjær, A., & Herz, J. (1999) · Nature Cell Biology · doi:10.1038/14109 · Cited by 217 · see citing works
Ramge, P., Unger, R. E., Oltrogge, J. B., Zenker, D., Begley, D. J., Kreuter, J., & von Briesen, H. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00078.x · Cited by 197 · see citing works
Self-citationKreuter, J., Petrov, V. E., Kharkevich, D. A., & Alyautdin, R. N. (1997) · Journal of Controlled Release · doi:10.1016/s0168-3659(97)00061-8 · Cited by 196 · see citing works
Self-citationFénart, L., Casanova, A., Dehouck, B., et al. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35204-8 · Cited by 196 · see citing works
Alyautdin, R. N., Gothier, D., Петров, Kharkevich, D. A., & Kreuter, J. (1995) · European Journal of Pharmaceutics and Biopharmaceutics · Cited by 148 · see citing works
Self-citationSchröder, U., & Sabel, B. A. (1996) · Brain Research · doi:10.1016/0006-8993(95)01375-x · Cited by 144 · see citing works
Friese, A. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(99)00073-9 · Cited by 140 · see citing works
Ji, Z.-S., Pitas, R. E., & Mahley, R. W. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13452 · Cited by 134 · see citing works
Efficacy of Oral Dalargin-loaded Nanoparticle Delivery across the Blood–Brain Barrier
Schröeder, U., Sommerfeld, P., & Sabel, B. A. (1998) · Peptides · doi:10.1016/s0196-9781(97)00474-9 · Cited by 106 · see citing works
The Blood-Brain Barrier and Drug Delivery to the CNS
(2000) · CRC Press eBooks · doi:10.1201/9780824741990 · Cited by 90 · see citing works
Ramge, P., Kreuter, J., & Lemmer, B. (1999) · Chronobiology International · doi:10.3109/07420529909016944 · Cited by 27 · see citing works
Self-citationUsing Nanoparticles to Target Drugs to the Central Nervous System
Alyautdin, R. N., & Kreuter, J. (2000) · CRC Press eBooks · doi:10.1201/9780824741990.ch11 · Cited by 12 · see citing works
Self-citationEl-Bachá, R. D. S., Lagrange, P., Grădinaru, D., Suleman, F. G., Minn, A., & Denizot, C. (2000) · CRC Press eBooks · doi:10.1201/9780824741990.ch9 · Cited by 9 · see citing works
Lipoproteins and Reconstituted Blood-Brain Barrier
Méresse, S., Dehouck, M., Delorme, P., Fruchart, J., & Cecchelli, R. (1991) · Springer eBooks · doi:10.1007/978-1-4757-0286-6_17 · Cited by 7 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles
Oberdörster, G., Oberdörster, E., & Oberdörster, J. (2005) · Environmental Health Perspectives · doi:10.1289/ehp.7339 · Cited by 7,891 · see citing works
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002 · see citing works
Translocation of inhaled ultrafine particles to the brain
Oberdörster, G., Sharp, Z., Atudorei, V., Elder, A., Gelein, R., Kreyling, W., & Cox, C. (2004) · Inhalation Toxicology · doi:10.1080/08958370490439597 · Cited by 2,606 · see citing works
Aggarwal, P., Hall, J. B., McLeland, C. B., Dobrovolskaia, M. A., & McNeil, S. E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.009 · Cited by 1,791 · see citing works
Nicolas, J., Mura, S., Brambilla, D., Mackiewicz, N., & Couvreur, P. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35265f · Cited by 1,270 · see citing works
Donaldson, K., Aitken, R., Tran, L., Stone, V., Duffin, R., Forrest, G., & Alexander, A. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj130 · Cited by 1,167 · see citing works
Deposition and biokinetics of inhaled nanoparticles
Geiser, M., & Kreyling, W. G. (2010) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-7-2 · Cited by 747 · see citing works
Transport of drugs across the blood–brain barrier by nanoparticles.
Wohlfart, S., Gelperina, S., & Kreuter, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.017 · Cited by 715 · see citing works
Self-citationDelivery of therapeutic agents to the central nervous system: the problems and the possibilities
Begley, D. J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.08.001 · Cited by 679 · see citing works
Drug delivery to the central nervous system by polymeric nanoparticles: What do we know?
Kreuter, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.008 · Cited by 554 · see citing works
Self-citationNanomaterials for Neural Interfaces
Kotov, N. A., Winter, J. O., Clements, I. P., Jan, E., Timko, B. P., Campidelli, S., Pathak, S., Mazzatenta, A., Lieber, C. M., Prato, M., et al. (2009) · Advanced Materials · doi:10.1002/adma.200801984 · Cited by 504 · see citing works
Solid lipid nanoparticles for targeted brain drug delivery.
BLASI, P., GIOVAGNOLI, S., SCHOUBBEN, A., RICCI, M., & ROSSI, C. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.011 · Cited by 506 · see citing works
Zensi, A., Begley, D., Pontikis, C., Legros, C., Mihoreanu, L., Wagner, S., Büchel, C., von Briesen, H., & Kreuter, J. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.03.002 · Cited by 438 · see citing works
Self-citationEvolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
S. Hersh, D., S. Wadajkar, A., B. Roberts, N., G. Perez, J., P. Connolly, N., Frenkel, V., A. Winkles, J., F. Woodworth, G., & J. Kim, A. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151221150733 · Cited by 387 · see citing works
The blood-brain barrier: structure, function and therapeutic approaches to cross it.
Tajes, M., Ramos-Fernández, E., Weng-Jiang, X., Bosch-Morató, M., Guivernau, B., Eraso-Pichot, A., Salvador, B., Fernàndez-Busquets, X., Roquer, J., & Muñoz, F. J. (2014) · Molecular Membrane Biology · doi:10.3109/09687688.2014.937468 · Cited by 380 · see citing works
Wilson, B., Samanta, M. K., Santhi, K., Kumar, K. P. S., Paramakrishnan, N., & Suresh, B. (2008) · Brain Research · doi:10.1016/j.brainres.2008.01.039 · Cited by 363 · see citing works
Scott, L. E., & Orvig, C. (2009) · Chemical Reviews · doi:10.1021/cr9000176 · Cited by 332 · see citing works
Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs
Naqvi, S., Panghal, A., & Flora, S. J. S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00494 · Cited by 305 · see citing works
Mohamed, F., & van der Walle, C. F. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21082 · Cited by 299 · see citing works
Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles
Kurakhmaeva, K. B., Djindjikhashvili, I. A., Petrov, V. E., Balabanyan, V. U., Voronina, T. A., Trofimov, S. S., Kreuter, J., Gelperina, S., Begley, D., & Alyautdin, R. N. (2009) · Journal of Drug Targeting · doi:10.1080/10611860903112842 · Cited by 221 · see citing works
Self-citationNeurotherapeutic applications of nanoparticles in Alzheimer’s disease
Sahni, J. K., Doggui, S., Ali, J., Baboota, S., Dao, L., & Ramassamy, C. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.033 · Cited by 219 · see citing works
Nanoscale drug delivery systems and the blood–brain barrier
Khalin, I., Alyautdin, R., Ismail, N. M., Haron, M. H., & Kuznetsov, D. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s52236 · Cited by 204 · see citing works
Self-citationLipid nanoparticle-mediated drug delivery to the brain
Khare, P., Edgecomb, S. X., Hamadani, C. M., Tanner, E. E. L., & S Manickam, D. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114861 · Cited by 187 · see citing works
Brown, T. D., Habibi, N., Wu, D., Lahann, J., & Mitragotri, S. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00743 · Cited by 182 · see citing works
Mechanism of polymeric nanoparticle-based drug transport across the blood-brain barrier (bbb).
Kreuter, J. (2013) · Journal of Microencapsulation · doi:10.3109/02652048.2012.692491 · Cited by 172 · see citing works
Self-citationLiu, G., Men, P., Kudo, W., Perry, G., & Smith, M. A. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.03.064 · Cited by 148 · see citing works
Uptake and permeability studies of BBB-targeting immunoliposomes using the hCMEC/D3 cell line.
Markoutsa, E., Pampalakis, G., Niarakis, A., Romero, I. A., Weksler, B., Couraud, P.-O., & Antimisiaris, S. G. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.11.015 · Cited by 122 · see citing works
Targeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases
Anthony, D. P., Hegde, M., Shetty, S. S., Rafic, T., Mutalik, S., & Rao, B. S. S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119326 · Cited by 110 · see citing works
Clinically approved liposomal nanomedicines: lessons learned from the biomolecular corona
Caracciolo, G. (2018) · Nanoscale · doi:10.1039/c7nr07450f · Cited by 106 · see citing works
Nanobiotechnology-based drug delivery to the central nervous system.
Jain, K. K. (2007) · Neurodegenerative Diseases · doi:10.1159/000101884 · Cited by 100 · see citing works
“These carriers can penetrate the BBB and deliver drugs of various structures, including peptides, hydrophilic compounds and lipophilic compounds that are otherwise eliminated from the brain by P-glycoprotein. When a suspension of polysorbate-coated PBCA nanoparticles is introduced into blood, apolipoproteins of the bl…”
BackgroundApolipoproteins: New players in cancers
He, Y., Chen, J., Ma, Y., & Chen, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1051280 · Cited by 52 · see citing works
Derakhshankhah, H., Sajadimajd, S., Jafari, S., Izadi, Z., Sarvari, S., Sharifi, M., Falahati, M., Moakedi, F., Muganda, W. C. A., Müller, M., et al. (2020) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2020.102149 · Cited by 48 · see citing works
- Authors
- Kreuter, J., Shamenkov, D., Petrov, V., Ramge, P., Cychutek, K., Koch-Brandt, C., & Alyautdin, R.
- Affiliations
- Goethe University Frankfurt (DE)
- Sechenov University (RU)
- Paul Ehrlich Institut (DE)
- Johannes Gutenberg University Mainz (DE)
- Venue
- Journal of drug targeting
- Publisher
- Informa UK Limited
- Published
- 2002-01
- Volume
- 10
- Issue
- 4
- Pages
- 317-325
- ISSN
- 1026-7158 (ISSN-L)
- 1061-186X
- 1029-2330
- OpenAlex
- W2018121350
- Cited by
- 801
- References
- 32
- Citations by year
- 2026: 14 · 2025: 21 · 2024: 35 · 2023: 37 · 2022: 24 · 2021: 44 · 2020: 62 · 2019: 39 · 2018: 36 · 2017: 33 · 2016: 48 · 2015: 39 · 2014: 43 · 2013: 48 · 2012: 46
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of drug targeting (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- blood-brain barrier, apolipoprotein E, apolipoprotein B, Tween 80, dalargin, loperamide, nanoparticle drug delivery, receptor-mediated endocytosis, transcytosis, ApoE-deficient mice, antinociception, brain drug delivery
- MeSH terms
- Animals, Apolipoproteins, Apolipoproteins E, Biological Transport, Blood-Brain Barrier, Male, Mice, Inbred C57BL, Mice, Inbred ICR, Mice, Transgenic, Pain Measurement, Polysorbates, Drug Delivery Systems, Nanotechnology, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
